ArticlemSphere2019
A Controlled Human Infection Model of Group A
Open access · goldAbstract read
In one paragraph
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- An emm-type specific qPCR to track bacterial load during experimental human Streptococcus pyogenes pharyngitis.BMC infectious diseases · 2021Trial
- Subclinical exposure to Streptococcus pyogenes drives the development of long-lived homologous immunity.Nature communications · 2026Article
- Revisiting the streptococcal M protein: modern perspectives on antibody function, host interactions, and therapeutic targeting.Frontiers in immunology · 2026Review
- The burden of group AiScience · 2025Review
- An oropharyngeal gonorrhoea controlled human infection model: a provisional protocol using a novelWellcome open research · 2025Article
- Streptococcus pyogenes pharyngitis elicits diverse antibody responses to key vaccine antigens influenced by the imprint of past infections.Nature communications · 2024Article
- Efficient and rapid one-step method to generate gene deletions inMicrobiology spectrum · 2024Article
- Molecular characterization ofMicrobial genomics · 2024Article
- Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model.PLoS neglected tropical diseases · 2024Article
- Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease-streptococcal vaccine development: a national heart, lung and blood institute workshop report.BMJ global health · 2023Review
- Article
- A human model of Buruli ulcer: The case for controlled human infection and considerations for selecting a Mycobacterium ulcerans challenge strain.PLoS neglected tropical diseases · 2023Review
- Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022.Immunotherapy advances · 2023Review
- Article
- Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling.The Journal of antimicrobial chemotherapy · 2022Article
- Genomic analysis of group AJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022Article
- Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial.Nature communications · 2022Article
- Human challenge trials in vaccine development.Seminars in immunology · 2020Review
- Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.Frontiers in immunology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Joshua OsowickiTropical Diseases, Murdoch Children's Research Institute, Melbourne, Victoria, Australia joshua.osowicki@rch.org.au andrew.steer@rch.org.au.ORCID 0000-0002-9432-6700
Kristy I AzzopardiTropical Diseases, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Liam McIntyreDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-3143-5192
Tania Rivera-HernandezSchool of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
Cheryl-Lynn Y OngSchool of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.ORCID 0000-0001-6036-6889
Ciara BakerTropical Diseases, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Christine M GillenSchool of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.ORCID 0000-0002-1775-3055
Mark J WalkerSchool of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
Pierre R SmeestersTropical Diseases, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-2642-9919
Mark R DaviesDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-6141-5179
Andrew C SteerTropical Diseases, Murdoch Children's Research Institute, Melbourne, Victoria, Australia joshua.osowicki@rch.org.au andrew.steer@rch.org.au.ORCID 0000-0001-7346-0196
The University of Queensland · AUMurdoch Children's Research Institute · AURoyal Children's Hospital · AUThe University of Melbourne · AUUniversité Libre de Bruxelles · BE
Funding
Biotechnology and Biological Sciences Research CouncilMedical Research Council MR/R005982/1Wellcome Trust
Abstract
Group A
Indexed as
AnimalsAnti-Bacterial AgentsDisease Models, AnimalGenome, BacterialHumansMiceMice, TransgenicPharyngitisPharynxStreptococcus pyogenesVirulenceVirulence FactorsWhole Genome SequencingAnti-Bacterial AgentsVirulence Factorscontrolled human infection modelgroup A Streptococcushuman challenge studypharyngitisStreptococcus pyogenesvaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.